Please login to the form below

Not currently logged in
Email:
Password:

Provenge

This page shows the latest Provenge news and features for those working in and with pharma, biotech and healthcare.

Valeant uncouples Dendreon and skincare brands to cut debt

Valeant uncouples Dendreon and skincare brands to cut debt

Dendreon's Provenge cancer vaccine. Canada's Valeant has agreed to sell off assets in two deals worth $2.1bn as it works to pay down high levels of debt. ... Meanwhile, the Dendreon deal comes two years after Valeant paid around $300m for the business,

Latest news

More from news
Approximately 9 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    Bringing in an additional $819.9m in cash, Valeant also sold its equity interest in Dendreon (manufacturer of Provenge, a personalised immunotherapy) to the Sanpower Group.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Corporate acquisition. 400. Dendreon/ Valeant Pharmaceuticals. PROVENGE (sipuleucel-T) and other assets - prostate cancer.

  • Pharma deals in February 2015 Pharma deals in February 2015

    This month saw the deadline, highlighted in January's Deal Watch, for Valeant to acquire Dendreon, and more specifically the dendritic cell, prostate cancer vaccine Provenge (sipuleucel-T), come and go.

  • Pharma deals during January 2015 Pharma deals during January 2015

    Staying with immuno-oncology, an acquisition in the making is the stalking horse bid of $400m cash from Valeant to acquire the rights to Dendreon's Provenge (sipuleucel-T) which are

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics